Care Rail

← Medical · All 20 for COVID-19 (residual / endemic)

Taiwan

COVID-19 (residual / endemic) · Infectious

High ambulatory volume; global budgets constrain growth. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via NHI single payer.

Rank in this country#25
Share of deaths1.1%
Master rank#25
System quality rank#12

Access & coverage

NHI single payer

NHI single payer with smart-card claims; low waiting

Treatment

  • Antivirals / antibiotics per stewardship rules
  • Hospital pathways for severe pneumonia / sepsis
  • Antiretroviral or TB regimens with public-health follow-up

Prevention

  • National immunization schedules
  • Surveillance, outbreak response, infection control in hospitals
  • Targeted screening (TB, HIV, hep) for risk groups

Lifestyle

  • Hygiene, ventilation awareness, staying home when infectious
  • Vaccination uptake as a social norm
  • Safer sex / harm reduction where relevant

What stands out here

Same broad infectious toolkit as peers — differences are coverage rules, wait times, prices, and follow-through.

vs master: -0.0 percentage points vs Top 20 average share.